Spencer Hauck

Spencer Hauck

Auto-generated profile, based on publicly available information

Spencer Hauck

Department of Pathology, Duke University School of Medicine, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BDBushu Dong
Bushu Dong
AJAlex M. Jaeger
Alex M. Jaeger
PHPhilip F. Hughes
Philip F. Hughes
DLDavid R. Loiselle
David R. Loiselle
JHJ. Spencer Hauck
J. Spencer Hauck
DTDennis J. Thiele
Dennis J. Thiele
Heat shock factor 1 (HSF1) is a cellular stress-protective transcription factor exploited by a wide range of cancers to drive proliferation, survival, invasion, and metastasis. Nuclear HSF1 abundance is a prognostic indicator for cancer severity, therapy resistance, and shortened patient survival. The HSF1 gene was amplified, and nuclear HSF1 abundance was markedly increased in prostate cancers and particularly in neuroendocrine prostate cancer (NEPC), for which there are no available treatment options. Despite genetic validation of HSF1 as a therapeutic target in a range of cancers, a direct and selective small-molecule HSF1 inhibitor has not been validated or developed for use in the clinic. We described the identification of a direct HSF1 inhibitor, Direct Targeted HSF1 InhiBitor (DTHIB), which physically engages HSF1 and selectively stimulates degradation of nuclear HSF1. DTHIB robustly inhibited the HSF1 cancer gene signature and prostate cancer cell proliferation. In addition, it potently attenuated tumor progression in four therapy-resistant prostate cancer animal models, including an NEPC model, where it caused profound tumor regression. This study reports the identification and validation of a direct HSF1 inhibitor and provides a path for the development of a small-molecule HSF1-targeted therapy for prostate cancers and other therapy-resistant cancers.

15 July 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JCJessica A. Chadwick
Jessica A. Chadwick
JHJ. Spencer Hauck
J. Spencer Hauck
JLJeovanna Lowe
Jeovanna Lowe
JSJeremiah J. Shaw
Jeremiah J. Shaw
DGDenis C. Guttridge
Denis C. Guttridge
JRJill A. Rafael‐Fortney
Jill A. Rafael‐Fortney
Early treatment with heart failure drugs lisinopril and spironolactone improves skeletal muscle pathology in Duchenne muscular dystrophy (DMD) mouse models. The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonist spironolactone indirectly and directly target MR. The presence and function of MR in skeletal muscle have not been explored. MR mRNA and protein are present in all tested skeletal muscles from both wild‐type mice and DMD mouse models. MR expression is cell autonomous in both undifferentiated myoblasts and differentiated myotubes from mouse and human skeletal muscle cultures. To test for MR function in skeletal muscle, global gene expression analysis was conducted on human myotubes treated with MR agonist (aldosterone; EC50 1.3 nM) or antagonist (spironolactone; IC50 1.6 nM), and 53 gene expression differences were identified. Five differences were conserved in quadriceps muscles from dystrophic mice treated with spironolactone plus lisinopril (IC 50 0.1 nM) compared with untreated controls. Genes down‐regulated more than 2‐fold by MR antagonism included FOS, ANKRD1 , and GADD45B , with known roles in skeletal muscle, in addition to NPR3 and SERPINA3, bona fide targets of MR in other tissues. MR is a novel drug target in skeletal muscle and use of clinically safe antagonists may be beneficial for muscle diseases.— Chadwick, J. A., Hauck, J. S., Lowe, J., Shaw, J. J., Guttridge, D. C., Gomez‐Sanchez, C. E., Gomez‐Sanchez, E. P., Rafael‐Fortney, J. A. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 29, 4544‐4554 (2015). www.fasebj.org

25 October 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
JHJ. Spencer Hauck
J. Spencer Hauck
ZHZachary M. Howard
Zachary M. Howard
JLJeovanna Lowe
Jeovanna Lowe
NRNeha Rastogi
Neha Rastogi
MPMadison G. Pico
Madison G. Pico
JRJill A. Rafael-Fortney
Jill A. Rafael-Fortney
Acute skeletal muscle injury is followed by a temporal response of immune cells, fibroblasts, and muscle progenitor cells within the muscle microenvironment to restore function. These same cell types are repeatedly activated in muscular dystrophy from chronic muscle injury, but eventually, the regenerative portion of the cycle is disrupted and fibrosis replaces degenerated muscle fibers. Mineralocorticoid receptor (MR) antagonist drugs have been demonstrated to increase skeletal muscle function, decrease fibrosis, and directly improve membrane integrity in muscular dystrophy mice, and therefore are being tested clinically. Conditional knockout of MR from muscle fibers in muscular dystrophy mice also improves skeletal muscle function and decreases fibrosis. The mechanism of efficacy likely results from blocking MR signaling by its endogenous agonist aldosterone, being produced at high local levels in regions of muscle damage by infiltrating myeloid cells. Since chronic and acute injuries share the same cellular processes to regenerate muscle, and MR antagonists are clinically used for a wide variety of conditions, it is crucial to define the role of MR signaling in normal muscle repair after injury. In this study, we performed acute injuries using barium chloride injections into tibialis anterior muscles both in myofiber MR conditional knockout mice on a wild-type background (MRcko) and in MR antagonist-treated wild-type mice. Steps of the muscle regeneration response were analyzed at 1, 4, 7, or 14 days after injury. Presence of the aldosterone synthase enzyme was also assessed during the injury repair process. We show for the first time aldosterone synthase localization in infiltrating immune cells of normal skeletal muscle after acute injury. MRcko mice had an increased muscle area infiltrated by aldosterone synthase positive myeloid cells compared to control injured animals. Both MRcko and MR antagonist treatment stabilized damaged myofibers and increased collagen infiltration or compaction at 4 days post-injury. MR antagonist treatment also led to reduced myofiber size at 7 and 14 days post-injury. These data support that MR signaling contributes to the normal muscle repair process following acute injury. MR antagonist treatment delays muscle fiber growth, so temporary discontinuation of these drugs after a severe muscle injury could be considered.

1 June 2017 in Physiological Genomics
Verified
Journal Article
Closed access
PDF file
JCJessica A. Chadwick
Jessica A. Chadwick
JHJ. Spencer Hauck
J. Spencer Hauck
CGCelso E. Gomez-Sanchez
Celso E. Gomez-Sanchez
EGElise Gomez-Sanchez
Elise Gomez-Sanchez
JRJill A. Rafael-Fortney
Jill A. Rafael-Fortney
Mineralocorticoid and glucocorticoid receptors are closely related steroid hormone receptors that regulate gene expression through many of the same hormone response elements. However, their transcriptional activities and effects in skeletal muscles are largely unknown. We recently identified mineralocorticoid receptors (MR) in skeletal muscles after finding that combined treatment with the angiotensin-converting enzyme inhibitor lisinopril and MR antagonist spironolactone was therapeutic in Duchenne muscular dystrophy mouse models. The glucocorticoid receptor (GR) agonist prednisolone is the current standard-of-care treatment for Duchenne muscular dystrophy because it prolongs ambulation, likely due to its anti-inflammatory effects. However, data on whether glucocorticoids have a beneficial or detrimental direct effect on skeletal muscle are controversial. Here, we begin to define the gene expression profiles in normal differentiated human skeletal muscle myotubes treated with MR and GR agonists and antagonists. The MR agonist aldosterone and GR agonist prednisolone had highly overlapping gene expression profiles, supporting the notion that prednisolone acts as both a GR and MR agonist that may have detrimental effects on skeletal muscles. Co-incubations with aldosterone plus either nonspecific or selective MR antagonists, spironolactone or eplerenone, resulted in similar numbers of gene expression changes, suggesting that both drugs can block MR activation to a similar extent. Eplerenone treatment alone decreased a number of important muscle-specific genes. This information may be used to develop biomarkers to monitor clinical efficacy of MR antagonists or GR agonists in muscular dystrophy, develop a temporally coordinated treatment with both drugs, or identify novel therapeutics with more specific downstream targets.

13 February 2019 in Human Molecular Genetics
Verified
Journal Article
Closed access
JHJ Spencer Hauck
J Spencer Hauck
JLJeovanna Lowe
Jeovanna Lowe
NRNeha Rastogi
Neha Rastogi
KMKevin E McElhanon
Kevin E McElhanon
JPJennifer M Petrosino
Jennifer M Petrosino
JRJill A Rafael-Fortney
Jill A Rafael-Fortney

12 December 2023 in The Prostate
Verified
Journal Article
Closed access
DMDavid Moon
David Moon
JHJ. Spencer Hauck
J. Spencer Hauck
XJXue Jiang
Xue Jiang
HQHolly Quang
Holly Quang
LXLingfan Xu
Lingfan Xu
JHJiaoti Huang
Jiaoti Huang